Natpar (parathyroid hormone) 100 micrograms/dose powder and solvent for solution for injection: expected shortage from June 30th, 2022.

Summary:

• Due to manufacturing challenges, Takeda will be unable to supply the 100 micrograms/dose strength from approximately end of June 2022. The duration is unknown but is expected to last at least 6 months.
• Healthcare professionals are advised not to initiate any new patients on any strength of Natpar until the supply issue is resolved.
• For existing patients on 100 mcg once a day, once the 100 micrograms / dose strength is unavailable, healthcare professionals can prescribe an alternative dosing regimen, as per their independent clinical judgment (see details below).
• It is very important to closely monitor serum calcium levels and observe patients for signs and symptoms of hypocalcemia while carefully adjusting active vitamin D and supplemental calcium doses in all patients affected by Natpar 100 micrograms/dose shortage.